I-MAB ADR IMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMAB is a good fit for your portfolio.
News
-
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
-
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
-
I-Mab to Participate at the Jefferies Global Healthcare Conference
-
I-MAB Filed 2023 Annual Report on Form 20-F
-
ADRs Slump; FLJ Group Declines 21%
-
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.50–1.61
- 52-Week Range
- $1.16–3.17
- Bid/Ask
- $1.56 / $1.60
- Market Cap
- $129.41 Mil
- Volume/Avg
- 153,189 / 211,925
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 7.12%
Company Profile
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 220
- Website
- https://www.i-mabbiopharma.com
Valuation
|
Metric
|
IMAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | 34.08 |
Price/Cash Flow | — |
Price/Earnings
IMAB
Financial Strength
|
Metric
|
IMAB
|
|---|---|
Quick Ratio | 5.59 |
Current Ratio | 5.67 |
Interest Coverage | −2,100.72 |
Quick Ratio
IMAB
Profitability
|
Metric
|
IMAB
|
|---|---|
Return on Assets (Normalized) | −32.51% |
Return on Equity (Normalized) | −46.87% |
Return on Invested Capital (Normalized) | −47.12% |
Return on Assets
IMAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Kvcvpkst | Xfxzk | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Crzwfjd | Nywpz | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Grwrczzj | Gvnskk | $114.0 Bil | |||
| Moderna Inc
MRNA
| Kryfqvlt | Whyz | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cmkvdzc | Kdqmk | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Tbczcsjl | Ncmfp | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Tptrvdbz | Rjlf | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jqghcvv | Mgdbpc | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Ksvgvhjp | Vrwp | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bxxwhqbhgl | Zvnhvrd | $11.6 Bil |